HOME >> MEDICINE >> NEWS
Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

is developing advanced drugs and vaccines for cancer and infectious diseases. Maxim's focus is to develop novel products that include pharmacoeconomic and disease management benefits such as out-patient therapy, improved clinical efficacy, higher level of safety, cost-effective treatment and improved patient compliance. The Company has initiated three Phase III cancer clinical trials for its lead product Maxamine in the U.S., Europe and Australia for malignant melanoma and acute myelogenous leukemia. Phase II trials of Maxamine Therapy are ongoing or planned for other cancer indications such as renal cell carcinoma and prostate adenocarcinoma. The Company also plans to test Maxamine Therapy in a Phase II clinical trial for the treatment of hepatitis C patients. The Company's secondary platform technology, MaxVax®, now in preclinical development, utilizes a mucosal vaccine carrier/adjuvant system for a broad range of infectious diseases. The Company expects to commercialize its technologies through a combination of in-house development and collaborative agreements with pharmaceutical companies.

This news release contains certain forward-looking statements that involve risks and uncertainties. The Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include, but are not limited to, those discussed under "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K for the year ended September 30, 1997 and the Company's Registration Statement on Form S-3 (File No. 333-65011), each as amended through the date hereof, as filed with the Securities and Exchange Commission, including the uncertainties associated with patent protection, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that clinical trials will not commence when planned, and the risk that the Company wi
'"/>

Contact: Amy Flood
a.flood@noonanrusso.com
415-677-4455 x211
Noonan/Russo Communications
7-Dec-1998


Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... (PRWEB) , ... November 15, 2018 , ... Through its ... research support in study design, planning, sample collection, and analysis to a team of ... randomized controlled trial to test the effects on the microbiome of a low-fat diet ...
(Date:11/15/2018)... ... November 15, 2018 , ... The National Cancer Institute ... advancing age is the primary risk factor for cancer and we typically associate the ... the age of 45. And with aggressive treatment and advanced therapies, increasing numbers of ...
(Date:11/15/2018)... ... November 15, 2018 , ... West Virginia and Mississippi may have the two ... when it comes to the number of weight-loss surgeries per capita, and have two ... determine utilization of bariatric surgery in the 50 states plus the nation’s capital. The ...
(Date:11/15/2018)... ... November 15, 2018 , ... Access today announced that ... eForms solution for hospitals . This release features tight integration with Epic, Cerner, ... any of these systems, have patients electronically sign them on tablets, and then ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... release of “Loneliness in Our Human Code”, ( https://www.goinvo.com/vision/loneliness-in-our-human-code/ ) the latest in ... Health. This visual essay explores how social determinants of health, with a focus ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... , ... Triple W, an innovator of connected health devices, today announced the ... DFree®, the first wearable device for incontinence that notifies the user when it’s time ... with bladder control issues have a convenient and cost-effective alternative to disposable diapers or ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... and reconstructive surgery in their lives will soon be able to access a ... of work, Alton Ingram, MD, created the now-popular blog website http://www.draltoningrammd.com/ ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... healthcare organizations, today announced a strategic partnership with Formativ Health, a technology-enabled, ... Connector will perform platform integrations that connect Formativ Health’s clients’ Healthcare IT ...
Breaking Medicine Technology:
Cached News: